Could that report be the impetus for another prolonged bout of shorting? Why not. It seems that whatever excuse is needed to rally the shorts can be manufactured at any time . They can keep this up until there is overwhelming evidence of the superiority of the Ariad drugs compared to the competition, likely at ASH at least as regards 113. There are no surprises here, just more of the same dirty business by the same players.
Market Data 
Markets 
AI
